BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin
28.8.2026 15:34:00 CEST | Business Wire | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin.
Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130.
BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing.
Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said:
“BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are proud that Gabriele, Aleksandra, Lalu and the entire BLK team represent another example of the competitiveness of the Enry’s Model compared with traditional incubation, acceleration and venture-building models.”
The listing at a glance
BLK operates through a digital peer-to-peer marketplace for the trading and logistics of commodities.
Issued share capital: 16,666,375 shares
Reference price: €2.92 per share
Implied market capitalization: €48.7 million
FY2025 revenue: £20.7 million, +276% compared with £5.5 million in FY2024
FY2025 adjusted EBITDA: £1.05 million
Commodities traded on the platform: more than $15 billion as of December 2025
The admission was completed through a direct listing, with no issuance of new shares and no capital raise.
Assiduous acted as Listing Sponsor, bringing its Neo Sponsor® model to Dublin, a model that has already been used for more than 170 listings on the Euronext Access markets in Paris, Brussels and Lisbon.
A new milestone for Enry’s Island
BLK’s listing represents the **second transaction of this kind among Enry’s Island portfolio companies within a two-year period**, with a third IPO already in preparation.
Enry’s Island, listed on the Vienna Stock Exchange (WBAG:EIOS) since 2023, supports its portfolio companies throughout a development path that can begin with incubation and acceleration and, following years of growth, ultimately lead to the public markets.
Luigi Valerio Rinaldi, Chairman & CEO of Enry’s Island S.p.A., said:
“IPOs represent one of the most ambitious value-creation strategies for our assets. Having already achieved two portfolio company listings on two different international stock exchanges, with a third one on the way, confirms the direction we have taken and the validity of our model. Results are achieved through a disciplined approach, without shortcuts.”
With BLK’s listing, the publicly listed companies within the Enry’s Island ecosystem now have an aggregate value of approximately €100 million, in addition to more than 20 private companies within the ecosystem.
Gabriele Dadò, CEO of BLK, added:
“Euronext Access Dublin represents an ideal starting point for BLK’s next phase of growth, enabling us to strengthen the company’s public profile and broaden access to international capital and partners.”
Towards Gaming: Web2 Best Practices for the New Portfolio Companies
Enry’s Island S.p.A. also commented:
“We are proud of the traction achieved by the Web2 segment of our companies and confident that we will transfer these best practices to our new portfolio companies in the gaming sector, where incredible partnerships and new developments on the island are about to generate a visible impact on the international VC scene. Our goal is to be the first to create value around the best future leaders in the gaming world.
The very best will be invited to take part in our reality show, which we will produce in our phygital arena, RVA, creating a new way of experiencing and communicating with the global startup community, particularly in the gaming sector. Stay tuned. On TV.”
With BLK’s listing, Enry’s Island S.p.A. continues to demonstrate its pioneering vision, standing alongside its portfolio companies throughout their entire journey — from incubation to the public markets — and transforming every new listing into a shared milestone for the entire ecosystem.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260828239810/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer16.9.2026 08:00:00 CEST | Press release
An expert in scaling medical innovations, Marion Ghibaudo joins Okomera as the company advances toward industrial deployment. Okomera, a TechBio company pioneering next-generation cancer care through the development of a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the appointment of Marion Ghibaudo as Chief Technology Officer. She will spearhead the company’s technology and innovation strategy and lead the industrial deployment of its integrated hardware, software, and biological platform. Marion Ghibaudo will join Okomera’s Executive Committee and report to CEO Silvère Lucquin. In parallel, Raphaël Tomasi, Okomera’s co-founder and former CTO, transitions to the role of VP Platform, ensuring continuity in the development of the company’s technology platform. Marion’s appointment comes at a key stage in Okomera’s growth as the company advances toward pilot studies, industrial scale-up, and commercialization. Okomer
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing16.9.2026 07:00:00 CEST | Press release
Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1 These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3 Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its
Nippon Electric Glass’s IR Transmitting Glass “FI-02” Adopted for Heimann Sensor Lens Unit, Enabling a 120° × 68° Field of View16.9.2026 03:00:00 CEST | Press release
Nippon Electric Glass Co., Ltd. (NEG) (TOKYO: 5214), a global leader in specialty glass headquartered in Otsu, Japan, announced that its IR Transmitting Glass (chalcogenide glass) “FI-02” has been adopted for Heimann Sensor GmbH’s wide-angle lens unit for thermal cameras. The lens unit achieves a 120° × 68° field of view, surpassing the previous product’s maximum of 92° × 59°. The adoption marks a significant milestone for FI-02 and showcases how advanced specialty glass can meet the demanding optical and manufacturing requirements of the expanding infrared sensing market. Thermal cameras detect infrared radiation emitted by people or objects and convert it into thermal images. Infrared sensors can detect the locations of people and temperature distributions. They are expected to be used for people detection and monitoring, where privacy considerations are important, and for air-conditioning control, while their use is expanding in healthcare, equipment monitoring, and security. Advanc
Workiva Advances Regulatory Work with AI Innovation15.9.2026 17:00:00 CEST | Press release
Agent Studio anchors AI capabilities unveiled at Amplify 2026 Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the
Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 15:15:00 CEST | Press release
New Study Indicates Non-Pharmacological Aerosol May Provide Therapeutic Relief for Respiratory Conditions Provoked by the Atmospheric Aridity Inherent to Heatwaves SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom